World's Best Scientists 2026 revealed!

D-Index & Metrics

Psychology

D-Index
73
Citations
21744
World Ranking
1951
National Ranking
1142

Overview

Jan Fawcett is affiliated with the University of New Mexico in the United States. Their research spans multiple fields within medicine and psychology, with a focus on topics related to mental health, pain management, and oncology.

Their recent publications cover a range of areas including opioid use disorder treatment, depression, and lymphoma diagnosis. Notable papers include:

  • Pramipexole Augmentation of Buprenorphine Improves Pain and Depression in Opioid Use Disorder (2020), published in The Primary Care Companion For CNS Disorders
  • PAULA J. CLAYTON, MD (2021), published in Depression and Anxiety
  • 326 | GLOFITAMAB AND EPCORITAMAB FOR LARGE B CELL LYMPHOMA IN 319 REAL WORLD PATIENTS: A RETROSPECTIVE UK ANALYSIS OF EFFICACY, TOLERABILITY AND PRACTICAL IMPLICATIONS (2025), published in Hematological Oncology

Fawcett frequently collaborates with other researchers in the field. Key coauthors include:

  • A. John Rush
  • Rodrigo Escalona
  • Katie A. Busch
  • Ray DePaulo
  • John F. Greden

Their work has been published in a variety of journals, with major publication venues including:

  • The Primary Care Companion For CNS Disorders
  • Depression and Anxiety
  • Hematological Oncology

Jan Fawcett's main fields of study are:

  • Medicine
  • Psychology

Their research extends to several subfields, notably:

  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Anesthesiology and Pain Medicine
  • Experimental and Cognitive Psychology
  • Social Psychology

Key topics addressed in their research include:

  • Opioid Use Disorder Treatment
  • Treatment of Major Depression
  • Pain Management and Opioid Use
  • Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Maternal Mental Health During Pregnancy and Postpartum
  • Mental Health Treatment and Access
  • Lymphoma Diagnosis and Treatment

Best Publications

  • Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis

    Jay C. Fournier;Robert J. DeRubeis;Steven D. Hollon;Sona Dimidjian

  • A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

    Martin B. Keller;James P. McCullough;Daniel N. Klein;Bruce Arnow

  • Time-related predictors of suicide in major affective disorder

    Jan Fawcett;William A. Scheftner;Louis Fogg;David C. Clark

  • Clinical correlates of inpatient suicide.

    Katie A. Busch;Jan A. Fawcett;Douglas G. Jacobs

  • Practice guideline for the treatment of patients with bipolar disorder

    R. M A Hirschfeld;P. J. Clayton;I. Cohen;J. Fawcett

  • Clinical predictors of suicide in patients with major affective disorders: a controlled prospective study.

    Jan Fawcett;William Scheftner;David Clark;Don Hedeker

  • Assessing Anhedonia in Psychiatric Patients: The Pleasure Scale

    Jan Fawcett;David C. Clark;William A. Scheftner;Robert D. Gibbons

  • Catecholamine Metabolism, Depressive Illness, and Drug Response

    James W. Maas;Jan A. Fawcett;Haroutune Dekirmenjian

  • Clinical management--imipramine/placebo administration manual. NIMH Treatment of Depression Collaborative Research Program.

    J Fawcett;P Epstein;S J Fiester;I Elkin

  • Treatment Received by Depressed Patients

    Martin B. Keller;Gerald L. Klerman;Philip W. Lavori;Jan A. Fawcett

  • Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression

    Jan Fawcett;Robert L Barkin

  • 3-Methoxy-4-Hydroxy Phenylglycol (MHPG) Excretion in Depressive States: A Pilot Study

    James W. Maas;Jan Fawcett;Haroutune Dekirmenjian

  • Maintenance Phase Efficacy of Sertraline for Chronic Depression: A Randomized Controlled Trial

    M B Keller;J H Kocsis;M E Thase;A J Gelenberg

  • The Treatment of Chronic Depression, Part 2: A Double-Blind, Randomized Trial of Sertraline and Imipramine

    Martin B. Keller;Alan J. Gelenberg;Robert M.A. Hirschfeld;A. John Rush

  • Anxiety syndromes and their relationship to depressive illness.

    Jan Fawcett;Howard M. Kravitz

  • Stable trait components of hopelessness: baseline and sensitivity to depression

    Michael A. Young;Louis F. Fogg;William Scheftner;Jan Fawcett

  • Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.

    Michael E. Thase;A. John Rush;Robert H. Howland;Susan G. Kornstein

  • Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.

    Jay D. Amsterdam;Felipe Garcia-Espana;Jan Fawcett;Frederick M. Quitkin

  • Depression and MHPG excretion. Response to dextroamphetamine and tricyclic antidepressants.

    Jan Fawcett;James W. Maas;Haroutune Dekirmenjian

  • Gender differences in the clinical features of unipolar major depressive disorder.

    Michael A. Young;William A. Scheftner;Jan Fawcett;Gerald L. Klerman

  • A Meta-Analysis of Eight Randomized, Double-Blind, Controlled Clinical Trials of Mirtazapine for the Treatment of Patients With Major Depression and Symptoms of Anxiety

    Jan Fawcett;Robert L. Barkin

Frequent Co-Authors

Michael A. Young
Michael A. Young Illinois Institute of Technology
William Coryell
William Coryell University of Iowa
Robert J. DeRubeis
Robert J. DeRubeis University of Pennsylvania
Jean Endicott
Jean Endicott Columbia University
Michael E. Thase
Michael E. Thase University of Pennsylvania
Steven D. Hollon
Steven D. Hollon Vanderbilt University
Daniel N. Klein
Daniel N. Klein Stony Brook University
Lorrin M. Koran
Lorrin M. Koran Stanford University
Mauricio Tohen
Mauricio Tohen University of New Mexico
John C. Markowitz
John C. Markowitz Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying psychology in the USA opens doors to a range of online degrees and specialized career paths, including substance abuse counseling. As the demand for mental health professionals continues to rise, many states offer flexible online programs to help students gain the necessary skills and certifications.

For those interested in becoming a counselor, it’s important to note that education and certification requirements vary by location. For example, Arlington substance abuse counselors education requirements often include a combination of academic training and supervised clinical hours. In contrast, those looking at becoming a substance abuse counselor in Atlanta will find different criteria, such as distinct licensure exams and professional standards.

Prospective counselors should also review substance abuse counselor requirements in Aurora, which outline educational prerequisites and certification steps. Similarly, Austin substance abuse counselor certification requirements provide guidance on local pathways and continuing education.

By exploring these regional guidelines, students can select the online degree that best fits their career aspirations and state requirements, supporting a successful entry into the field of psychology and counseling.

Best Scientists Citing Jan Fawcett

Trending Scientists

Recently Published Articles